Petros Pharmaceuticals Price To Sales vs. Number Of Shares Shorted
| PTPI Stock | USD 0.27 0.02 6.90% |
Petros Pharmaceuticals Price To Sales Ratio |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.46 | 0.7198 |
|
|
For Petros Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Petros Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Petros Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Petros Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Petros Pharmaceuticals over time as well as its relative position and ranking within its peers.
Petros |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Petros Pharmaceuticals. If investors know Petros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Petros Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.80) | Revenue Per Share 0.99 | Quarterly Revenue Growth (0.29) | Return On Assets (0.31) | Return On Equity (0.64) |
The market value of Petros Pharmaceuticals is measured differently than its book value, which is the value of Petros that is recorded on the company's balance sheet. Investors also form their own opinion of Petros Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Petros Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Petros Pharmaceuticals' market value can be influenced by many factors that don't directly affect Petros Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Petros Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Petros Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Petros Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Petros Pharmaceuticals Number Of Shares Shorted vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Petros Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Petros Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Petros Pharmaceuticals is regarded third in price to sales category among its peers. It also is regarded third in number of shares shorted category among its peers making about 305,084 of Number Of Shares Shorted per Price To Sales. As of now, Petros Pharmaceuticals' Price To Sales Ratio is increasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Petros Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Petros Number Of Shares Shorted vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Petros Pharmaceuticals |
| = | 0.66 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Petros Pharmaceuticals |
| = | 200.56 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Petros Number Of Shares Shorted Comparison
Petros Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Petros Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Petros Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Petros Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Petros Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Petros Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -368.1 M | -349.7 M | |
| Net Loss | -10.3 M | -10.9 M | |
| Income Tax Expense | 5.7 B | 5.9 B | |
| Net Interest Income | -253.3 K | -266 K | |
| Operating Income | -13.6 M | -14.3 M | |
| Net Loss | -12.7 M | -13.3 M | |
| Income Before Tax | -8.2 M | -8.6 M | |
| Total Other Income Expense Net | 5.5 M | 5.7 M | |
| Net Loss | -8.2 M | -8.6 M | |
| Interest Income | 301.9 K | 317 K | |
| Change To Netincome | 4.4 M | 6.2 M | |
| Net Loss | (3.75) | (3.94) | |
| Income Quality | 0.93 | 0.98 | |
| Net Income Per E B T | 1.21 | 0.85 |
Petros Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Petros Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Petros Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Petros Pharmaceuticals' important profitability drivers and their relationship over time.
Use Petros Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Petros Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Petros Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Petros Pharmaceuticals Pair Trading
Petros Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Petros Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Petros Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Petros Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Petros Pharmaceuticals to buy it.
The correlation of Petros Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Petros Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Petros Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Petros Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Petros Pharmaceuticals position
In addition to having Petros Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 71 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. For more detail on how to invest in Petros Stock please use our How to Invest in Petros Pharmaceuticals guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
To fully project Petros Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Petros Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Petros Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.